BACKGROUND: Increasing numbers of tyrosine kinase inhibitors (TKIs) were studied and
approved for therapy of malignancies and other diseases. The aim of this study was to …

… tyrosine kinase inhibitors in human plasma. Following their extraction from human plasma, …
of the investigated tyrosine kinase inhibitors in human plasma and can be efficiently applied …

Background: A sensitive liquid chromatography coupled with tandem mass spectrometry (MS/MS)
method for the analysis in a small volume of plasma of 14 tyrosine kinase inhibitors …

Tyrosine kinase inhibitors (TKIs) are used to treat a number of cancers, including chronic
myeloid leukaemia and hepatocellular carcinoma. Therapeutic drug monitoring (TDM) may be …

… kinase inhibitors (afatinib, axitinib, bosutinib, cabozantinib, dabrafenib, lenvatinib, nilotinib,
osimertinib, ruxolitinib, and trametinib) in human serum and plasma … of blank human plasma …

… Quantification of gefitinib in human plasma can be achieved using liquid-liquid extraction and
… Gefitinib is stable in human plasma for 24 hours if stored at room temperature and for up to …

… The sample pretreatment consisted of protein precipitation with acetonitrile using a small
plasma … and has successfully been applied to routine TDM service for tyrosine kinase inhibitors. …

Small molecule kinase inhibitors (KIs) are a rapidly expanding class of narrow therapeutic
index antineoplastic drugs that exhibit substantial inter-individual variability in exposure. This …

… In recent years, more than 50 tyrosine kinase inhibitors (TKIs) … standard were extracted
from human plasma. Salting-out … accuracy was further assessed in plasma with a degree of …

… Pazopanib is a highly potent kinase inhibitor (table I) against vascular endothelial growth …
(IC 50 71–84 nmol/L) and c-kit receptor tyrosine kinases (IC 50 74 nmol/L), and is less potent …